Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedJun 18, 2026
DataAggregated Company Financials
Companies1402
  • 7D-0.7%
  • 3M4.3%
  • 1Y14.7%
  • YTD-2.7%

Last week, the Healthcare industry hasn't moved much but Moderna is up 34% in that time. The past year has been better, since the industry has gained 15% in that time. Earnings are forecast to grow by 18% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 18 Jun 2026US$6.5tUS$3.3tUS$122.0b23x52.9x1.9x
Sat, 16 May 2026US$6.7tUS$3.3tUS$122.7b22.7x54.5x2x
Mon, 13 Apr 2026US$6.2tUS$3.3tUS$127.2b22.7x48.8x1.9x
Wed, 11 Mar 2026US$6.4tUS$3.3tUS$124.4b25x51.7x2x
Fri, 06 Feb 2026US$6.5tUS$3.2tUS$126.3b27x51.7x2x
Sun, 04 Jan 2026US$6.5tUS$3.2tUS$135.6b25.7x47.8x2x
Tue, 02 Dec 2025US$6.5tUS$3.2tUS$133.5b25.9x48.9x2.1x
Thu, 30 Oct 2025US$6.1tUS$3.1tUS$137.4b25.2x44.1x1.9x
Sat, 27 Sep 2025US$5.6tUS$3.1tUS$137.6b23.6x40.7x1.8x
Mon, 25 Aug 2025US$5.7tUS$3.1tUS$137.2b23.7x41.8x1.9x
Wed, 23 Jul 2025US$5.4tUS$3.0tUS$128.4b24.9x41.9x1.8x
Fri, 20 Jun 2025US$5.5tUS$3.0tUS$127.5b22.8x42.8x1.8x
Sun, 18 May 2025US$5.4tUS$3.0tUS$126.1b23.3x42.9x1.8x
Tue, 15 Apr 2025US$5.3tUS$2.6tUS$82.2b25.4x64.6x2x
Thu, 13 Mar 2025US$5.7tUS$2.6tUS$78.6b25.9x72.2x2.1x
Sat, 08 Feb 2025US$5.9tUS$2.6tUS$89.7b26.5x65.9x2.2x
Mon, 06 Jan 2025US$5.8tUS$2.9tUS$79.3b27.3x73.5x2x
Wed, 04 Dec 2024US$6.2tUS$2.9tUS$77.4b28.3x79.6x2.1x
Fri, 01 Nov 2024US$6.1tUS$2.9tUS$71.8b26.8x85.2x2.1x
Sun, 29 Sep 2024US$6.2tUS$2.9tUS$70.6b30.1x87.9x2.1x
Tue, 27 Aug 2024US$6.3tUS$2.8tUS$56.5b31.9x111.2x2.2x
Thu, 25 Jul 2024US$6.3tUS$2.8tUS$60.9b31.6x104.1x2.2x
Sat, 22 Jun 2024US$6.2tUS$2.8tUS$62.5b30x98.8x2.2x
Mon, 20 May 2024US$6.2tUS$2.8tUS$64.1b31.1x97.2x2.2x
Wed, 17 Apr 2024US$5.9tUS$2.8tUS$85.4b31.3x69.7x2.1x
Fri, 15 Mar 2024US$6.3tUS$2.8tUS$84.5b31.7x74.4x2.3x
Sun, 11 Feb 2024US$6.2tUS$2.8tUS$76.3b31.6x81x2.2x
Tue, 09 Jan 2024US$6.3tUS$2.8tUS$90.0b31.5x70.1x2.2x
Thu, 07 Dec 2023US$5.9tUS$2.8tUS$91.4b29.3x65.1x2.1x
Sat, 04 Nov 2023US$5.7tUS$2.8tUS$88.4b26.7x65x2x
Mon, 02 Oct 2023US$5.9tUS$2.8tUS$98.2b27.6x59.7x2.1x
Wed, 30 Aug 2023US$6.2tUS$2.8tUS$99.0b27.7x62.3x2.2x
Fri, 28 Jul 2023US$6.1tUS$2.7tUS$113.2b27.7x54x2.2x
Sun, 25 Jun 2023US$6.0tUS$2.7tUS$109.8b26.6x54.8x2.2x
Price to Earnings Ratio

54.8x


Total Market Cap: US$6.0tTotal Earnings: US$109.8bTotal Revenue: US$2.7tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 52.9x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 3.6% per year over the last three years.
  • Revenues for these companies have grown 7.0% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market1.98%
Healthcare-0.71%
Biotech4.63%
Healthcare Services-1.23%
Pharma-1.72%
Healthtech-1.88%
Medical Equipment-2.50%
Life Sciences-3.21%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 53.8x.
    • Analysts expect its future annual earnings growth (16.2%) to be largely in line with prior year's earnings growth.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 25% over the next 5 years.
  • However this is lower than its past earnings growth rate of 55% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 15% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MRNA ModernaUS$63.9628.8%
+US$5.7b		151.8%PS11.4x
RVMD Revolution MedicinesUS$162.919.2%
+US$2.9b		308.0%PB23.1x
NTRA NateraUS$231.285.5%
+US$1.7b		35.3%PS13.2x
VRTX Vertex PharmaceuticalsUS$451.621.5%
+US$1.7b		0.7%PE26.4x
HIMS Hims & Hers HealthUS$35.4722.9%
+US$1.5b		-41.9%PS3.5x

Latest News

PFE
US$25.21
Pfizer
7D
-3.7%
1Y
5.6%
QURE
US$46.37
uniQure
7D
72.9%
1Y
207.1%
ROIV
US$31.40
Roivant Sciences
7D
5.6%
1Y
174.5%
MRK
US$113.87
Merck
7D
-5.7%
1Y
43.6%
NTRA
US$231.28
Natera
7D
5.5%
1Y
35.3%
HIMS
US$35.47
Hims & Hers Health
7D
22.9%
1Y
-41.9%
ABBV
US$216.49
AbbVie
7D
-3.7%
1Y
16.7%
BMY
US$54.00
Bristol-Myers Squibb
7D
-5.1%
1Y
15.3%
CYTK
US$78.78
Cytokinetics
7D
13.7%
1Y
140.7%
LLY
US$1,098.57
Eli Lilly
7D
-5.4%
1Y
39.9%
MCK
US$750.63
McKesson
7D
-4.6%
1Y
3.0%
Analysis Article • Jun 17

McKesson (MCK) Stock Could Be 17.3% Undervalued After Loan Deal And Buybacks

McKesson (MCK) stock is in focus after a cluster of recent moves, including a US$2.25b senior secured term loan maturing in 2032, a minority sale in Medical-Surgical Solutions and ongoing share repurchases. See our latest analysis for McKesson. After a weaker quarter and a pullback that left the 90 day share price return down 14.66% and the year to date share price return down 4.62%, McKesson still has a 1 year total shareholder return of 8.87% and a very large 5 year total shareholder...
MRNA
US$63.96
Moderna
7D
28.8%
1Y
151.8%
AMGN
US$337.60
Amgen
7D
-4.6%
1Y
16.6%
VRTX
US$451.62
Vertex Pharmaceuticals
7D
1.5%
1Y
0.7%
Narrative Update • Jun 17

VRTX: Kidney Franchise And Pipeline Expansion Will Drive Future Stock Upside

Vertex Pharmaceuticals' latest narrative update reflects a modest recalibration in analyst price targets, with figures such as Truist's move to $542 and Wells Fargo's lift to $550 framed around analysts' view that the emerging kidney franchise can grow into blockbuster assets and broaden the company's portfolio. Analyst Commentary Recent Street research on Vertex Pharmaceuticals highlights a generally constructive tone, with bullish analysts pointing to the expanding kidney franchise and a series of upward price target revisions as key supports for the stock's valuation and growth narrative.
RVMD
US$162.91
Revolution Medicines
7D
9.2%
1Y
308.0%
JNJ
US$228.39
Johnson & Johnson
7D
-4.2%
1Y
51.5%